Biggest News Aggregation in the World
📰 Allogeneic News

Page 5 - Allogeneic News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Allogeneic. Real-time updates on events, politics, business and more.

Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference

Precision BioSciences, Inc. a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will... | March 27, 2023
Precision Biosciences Inc Lotte New York Palace Hotel Precision Biosciences Guggenheim Healthcare Talks Genomic Medicines Rare Disease Days

Theriva Biologics, Inc.: Theriva Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

- Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR - - Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with
United States Dennis Riedl Theriva Biologics Stevena Shallcross Mark Schroeder Chris Calabrese

Atara Biotherapeutics, Inc.: Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel)

Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the
United States Pierre Fabre Posttransplant Lymphoproliferative Schwierige Zeiten Laure Sgandurra Pascal Touchon

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting

Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic ModelsSAN DIEGO, Dec. ... | December 13, 2022
San Diego United States Karl Johan Malmberg Barbara Friedman Michels Sadelain Bob Valamehr

Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting

Transplanted hypoimmune -modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems... | December 11, 2022
United States United Kingdom Sonja Schrepfer Immunocompetent Allogeneic Christina Chaivorapol Adam Johnson

Tessa Therapeutics Ltd: Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)

Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in 43% of relapsed or refractory CD30-positive lymphomas treated with Tessa's "off the shelf" CD30.CAR
United States Baylor College Of Medicine Kostenloser Wertpapierhandel Ivan Horak Davidh Quach Dave Schemelia

Tessa Therapeutics Ltd: Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

New data from clinical trials of TT11 and TT11X to be featured in two oral podium presentations and a poster presentationSINGAPORE, Nov. 03, 2022 (Tessa), a clinical-stage cell therapy company developing
United States Baylor College Of Medicine Kostenloser Wertpapierhandel Davidh Quach Thomas Willemsen Sairah Ahmed

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science